`Filed: July 7, 2017
`
`
`
`
`
`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`_____________________________
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`_____________________________
`
`
`MYLAN PHARMACEUTICALS INC,
`Petitioner
`
`v.
`
`ICOS CORPORATION,
`Patent Owner
`
`
`
`
`
`_____________________________
`
`Case IPR2017-00323
`Patent No. 6,943,166
`_____________________________
`
`
`JOINT MOTION TO KEEP SETTLEMENT AGREEMENT
`AS BUSINESS CONFIDENTIAL INFORMATION PURSUANT
`TO 35 U.S.C. § 317
`
`
`
`Patent No. 6,943,166
`Case No. IPR2017-00323
`
`
`Pursuant to 35 U.S.C. § 317 and 37 C.F.R. § 42.74, Petitioner Mylan
`
`Pharmaceuticals Inc. (“Petitioner”) and Patent Owner ICOS Corporation (“Patent
`
`Owner”) (together, “the Parties”) jointly request to file the Settlement Agreements,
`
`submitted concurrently herewith as Exhibit 1038 to the Joint Motion to Terminate
`
`the Proceeding, in its entirety, as Business Confidential information. In accordance
`
`with 37 C.F.R. § 42.20(b), the Parties sought, and received, authorization via email
`
`from the Board to file this motion on July 6, 2017.
`
`If requested, the rules permit the parties to have any filed settlement
`
`agreement treated as business confidential information and kept separate from the
`
`files of the involved patent. 37 C.F.R. § 42.74(c). Indeed, the statute requires it. 35
`
`U.S.C. § 317(b).
`
`Petitioner and Patent Owner hereby request that the settlement agreement
`
`filed herewith as Exhibit 1038 be treated as business confidential information, be
`
`kept separate from the file of the above captioned IPR, and be made available only
`
`to Federal Government agencies on written request, or to any person on a showing
`
`of good cause pursuant to 35 U.S.C. § 317(b) and 37 C.F.R. § 42.74(c). In view of
`
`that request the settlement agreement has been filed for access by the “Parties and
`
`Board Only.”
`
`
`
`
`
`1
`
`
`
`Patent No. 6,943,166
`Case No. IPR2017-00323
`
`Dated: July 7, 2017
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Respectfully submitted,
`
`
`
`
`
`
`
`/ Steven W. Parmelee /
`Steven W. Parmelee
`Registration No. 31,990
`Wilson Sonsini Goodrich & Rosati
`701 Fifth Avenue, Suite 5100
`Seattle, WA 98104
`Tel.: 206-883-2542
`Email: sparmelee@wsgr.com
`
`Attorneys for Petitioner
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`/ Mark J. Feldstein /
`Mark J. Feldstein
`Registration No. 46,693
`Finnegan, Henderson, Farabow, Garrett &
`Dunner, LLP
`901 New York Avenue, NW
`Washington, DC 20001-4413
`Tel.: 202-408-4092
`Email: mark.feldstein@finnegan.com
`
`Attorneys for Patent Owner
`
`
`
`
`2
`
`
`
`Patent No. 6,943,166
`Case No. IPR2017-00323
`
`
`CERTIFICATE OF SERVICE
`
`
`
`Pursuant to 37 C.F.R. § 42.6(e), this is to certify that I caused to be served a
`
`true and correct copy of the foregoing Joint Motion to Keep Settlement Agreement
`
`as Business Confidential Information Pursuant to 35 U.S.C. § 317, by electronic
`
`service, on this 7th day of July 2017, on the Patent Owners as follows:
`
`Mark J. Feldstein
`Joshua L. Goldberg
`Yieyie Yang
`Maureen D. Queler
`Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
`901 New York Avenue, NW
`Washington, DC 20001-4413
`Email: mark.feldstein@finnegan.com
`Email: joshua.goldberg@finnegan.com
`Email: yieyie.yang@finnegan.com
`Email: maureen.queler@finnegan.com
`
`Mark J. Stewart
`Dan L. Wood
`Gerald P. Keleher
`Eli Lilly and Company
`Lilly Corporate Center
`Indianapolis, IN 46285
`Email: stewart_mark@lilly.com
`Email: wood_dan_l@lilly.com
`Email: keleher_gerald@lilly.com
`
`
`
`
`
`
`Dated: July 7, 2017
`
`
`
`
`Respectfully submitted,
`
`
`
`/ Steven W. Parmelee /
`Steven W. Parmelee, Lead Counsel
`Reg. No. 31,990
`
`
`
`
`
`3
`
`